Nepal Health Minister Pushes to Ease Medicine Shortages, With Cancer Drugs a Top Priority

Health and Food Hygiene Minister Nisha Mehta has ordered officials to move fast on medicine supply management as shortages continue to affect the market, with cancer drugs singled out as a critical priority.

After inspecting the Department of Drug Administration in Kathmandu, Mehta directed the agency to ensure the smooth supply of medicines and to prevent shortages of essential treatments. She also told officials to accelerate field inspections and approval work for companies waiting on distribution permits.

Why this matters

Medicine shortages can quickly turn into a public health crisis, especially when they affect cancer patients who depend on uninterrupted treatment schedules. Disruptions in the availability of oncology drugs can delay therapy and create added pressure on patients, hospitals, and pharmacists.

The minister’s intervention signals that the government is treating the issue as more than a routine supply-chain problem. By focusing on inspection backlogs and distribution approvals, the ministry is targeting two common bottlenecks that can slow medicines from reaching the market.

What the directive is aiming to fix

According to the news reports, Mehta’s instructions centered on three priorities: keeping essential medicines available, preventing shortages of critical drugs such as cancer treatments, and speeding up regulatory processes for companies seeking distribution permissions.

That combination suggests a broader effort to reduce friction in the pharmaceutical pipeline, from import or production to final distribution. In practice, faster approvals and more efficient oversight could help ease pressure on supply in the near term if they are implemented consistently.

The bigger picture

Access to cancer medicines is a persistent challenge in many health systems, where high costs, complex logistics, and regulatory delays can all affect availability. International research has shown that pooled procurement and coordinated purchasing can improve negotiating power and help stabilize access to oncology medicines, underscoring how important supply-chain planning is for cancer care.

For patients and providers in Nepal, the immediate question is whether the ministry’s directive will translate into quicker approvals and fewer stock gaps on pharmacy shelves. The success of the move will likely depend on how rapidly the Department of Drug Administration can process inspections and whether suppliers can respond to demand without further delays.